Cargando…

Duration and onset of action of high dose U‐500 regular insulin in severely insulin resistant subjects with type 2 diabetes

AIM: Although regular human U‐500 insulin (U‐500) is frequently used for insulin resistant type 2 diabetics, pharmacokinetic and pharmacodynamic studies in these individuals are lacking. We set out to determine the rate of onset, duration of action and total glucose lowering effect of two doses of U...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shrestha, Rupendra T., Kumar, Anjali F., Taddese, Abdisa, Khowaja, Ameer A., Moheet, Amir, Olawsky, Evan, Eberly, Lynn E., Seaquist, Elizabeth R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354819/ https://www.ncbi.nlm.nih.gov/pubmed/30815569 http://dx.doi.org/10.1002/edm2.41

Ejemplares similares

Delayed Response to U-500 Regular Insulin
por: Davidson, Mayer B.
Publicado: (2018)

Structural Alterations in Deep Brain Structures in Type 1 Diabetes
por: Filip, Pavel, et al.
Publicado: (2020)

Insulin Edema With Use of U-500 Regular Insulin in a Hybrid Closed-Loop Insulin Pump
por: Vasigh, Mostafa, et al.
Publicado: (2020)

MON-152 Less Is More: Human Regular U-500 Insulin
por: Lugo Lopez, Zahira, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects
por: de la Peña, Amparo, et al.
Publicado: (2011)

FRI654 Concentrated Regular U-500 Insulin In An Automated Insulin Delivery System: A Case Report
por: Aurora, John, et al.
Publicado: (2023)

U-500 Regular Insulin: Clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients
por: Davidson, Mayer B., et al.
Publicado: (2010)

Hypoglycemia mediated by paraneoplastic production of Insulin like growth factor–2 from a malignant renal solitary fibrous tumor – clinical case and literature review
por: Khowaja, Ameer, et al.
Publicado: (2014)

Infusion of N‐acetyl cysteine during hypoglycaemia in humans does not preserve the counterregulatory response to subsequent hypoglycaemia
por: Moheet, Amir, et al.
Publicado: (2020)

Development and Implementation of a U-500 Regular Insulin Program in a Federally Qualified Health Center
por: Shaw, Kathy F., et al.
Publicado: (2017)

Relationship Between Hypoglycemia Awareness Status on Clarke/Gold Methods and Counterregulatory Response to Hypoglycemia
por: Rubin, Nathan T, et al.
Publicado: (2022)

Heterogeneity in Epinephrine Response to Experimental Hypoglycemia in Type 1 Diabetes and Controls
por: Zhang, Yuan, et al.
Publicado: (2022)

Type 1 Diabetes and Impaired Awareness of Hypoglycemia Are Associated with Reduced Brain Gray Matter Volumes
por: Bednarik, Petr, et al.
Publicado: (2017)

Advancing Patient Safety and Access to Concentrated Insulin (U-500 Regular Insulin) in the Veterans Health Administration: A Clinician Education Program in the Primary Care Setting
por: Lutz-McCain, Stacey J., et al.
Publicado: (2018)

Human regular U‐500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study
por: Grunberger, George, et al.
Publicado: (2020)

Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial
por: Kabul, Samaneh, et al.
Publicado: (2016)

Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study
por: Eby, Elizabeth L, et al.
Publicado: (2015)

LBSUN294 Insulin-induced Abdominal Acanthosis Nigricans From High Doses Of Insulin U-500
por: Yap, Sara Elizabeth, et al.
Publicado: (2022)

Patient‐reported outcomes in a study of human regular U‐500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes
por: Chen, Jieling, et al.
Publicado: (2020)

SAT167 Risk Of Life Threatening Hypoglycemia When Using U-100 Insulin Syringes To Administer R U-500 Insulin
por: Rizwan, Tehlil, et al.
Publicado: (2023)

SAT-LB028 Efficacy and Safety of Pramlintide as an Adjunct to Insulin U500 Therapy in Veterans with Severe Insulin Resistance
por: Oprea, Mihaela, et al.
Publicado: (2019)

Erratum: Delayed Response to U-500 Regular Insulin. Clinical Diabetes 2018;36: 77–79 (DOI: 10.2337/cd16-0058)
por: Davidson, Mayer B.
Publicado: (2018)

Evaluating the Effect of U-500 Insulin Therapy on Glycemic Control in Veterans With Type 2 Diabetes
por: Granata, Joseph A., et al.
Publicado: (2015)

Celebrating 100 years of insulin with Dr Elizabeth Seaquist
por: Seaquist, Elizabeth
Publicado: (2021)

Human Regular 500 units/mL Insulin Therapy: A Review of Clinical Evidence and New Delivery Options
por: Sze, David, et al.
Publicado: (2018)

U500 Disposable Patch Insulin Pump: Results and Discussion of a Veterans Affairs Pilot Study
por: Martin, Christopher, et al.
Publicado: (2018)

Evaluation of a Conservative Pharmacist-led U-500R Insulin Management Protocol in the Primary Care Setting
por: Dumont, Cyndi, et al.
Publicado: (2020)

Prolonged hyperinsulinemia after subcutaneous injection of 2400 U regular insulin in a suicide attempt: Time course of serum insulin with frequent measurements
por: Hiromine, Yoshihisa, et al.
Publicado: (2012)

Glycemic Control in Hospitalized Patients with Diabetes Receiving Corticosteroids Using a Neutral Protamine Hagedorn Insulin Protocol: A Randomized Clinical Trial
por: Khowaja, Ameer, et al.
Publicado: (2018)

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100
por: Alexopoulos, Anastasia‐Stefania, et al.
Publicado: (2021)

Abstract 5: Similar hypoglycemia duration with once-weekly insulin icodec versus insulin glargine U100 in insulin naïve or experienced patients with T2D
por: Manjunath, Aparna, et al.
Publicado: (2022)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

OR30-02 Efficacy and Safety Comparison Between U100 Regular Human Insulin and U100 Rapid Acting Insulin When Delivered by a 24 Hour Wearable Insulin Delivery Device in Type 2 Diabetes
por: Mora, Pablo, et al.
Publicado: (2020)

Human Brain Glycogen Metabolism During and After Hypoglycemia
por: Öz, Gülin, et al.
Publicado: (2009)

Determinants of regular smoking onset in South Africa using duration analysis
por: Vellios, Nicole, et al.
Publicado: (2016)

Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes
por: Mora, Pablo F, et al.
Publicado: (2020)

Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes
por: Kapitza, Christoph, et al.
Publicado: (2010)

Cost and Utilization Comparisons Among Propensity Score-Matched Insulin Lispro and Regular Insulin Users
por: Hall, Jennifer A., et al.
Publicado: (2003)

Correction: Determinants of regular smoking onset in South Africa using duration analysis
Publicado: (2016)

Hypoglycaemia is reduced with use of inhaled Technosphere(®) Insulin relative to insulin aspart in type 1 diabetes mellitus
por: Seaquist, E. R., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3tq6eteug7jbdklg1srdu184bs